
Third-quarter sales rose more than half, while operating profit came in below analysts’ average estimate as costs increased.
arGEN-X reported third-quarter revenue of $1.72 billion, up more than half from a year earlier, as sales of its Vyvgart drug drove growth. Operating profit rose 40% to $486 million, but missed the $551 million average expected by analysts surveyed by Bloomberg.
The company said higher research and marketing costs weighed on results. Nearly all revenue came from Vyvgart, according to the report.
Net income attributable to shareholders was $506 million, compared with $344 million a year earlier.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.